Menu
ncarol.com
  • Home
  • Financial
  • Business
  • Education
  • Nyse
  • Yacht Buyer
  • Finance
  • Health
  • Stocks
ncarol.com

'Spot Detective' – Check your spots this summer
ncarol.com/10200678

Trending...
  • Inkdnylon Custom Apparel Launches Cost-Saving System for Promotional Products and Custom Apparel in Chicago
  • U.S. Government Contracts in Excess of 38 Million Secured Through Partner, Establishing Multi-Year Defense Revenue Platform Through 2032: $BLIS
  • Larry R. Wasion Highlights Jump Gate I: Time Chair. The Opening Novel in His Expansive Science Fiction Series
The Spot Detective - who are they The Spot Detective - freckle
The latest campaign urging Australians to get their skin checked

MELBOURNE, Australia & SYDNEY - ncarol.com -- OncoBeta, a leading medical device company specialising in innovative epidermal radioisotope therapies for non-melanoma skin cancer, has launched The Spot Detective campaign to rally Australians in the fight against skin cancer this summer.

With two out of three Australians diagnosed with skin cancer before the age of 701, it is vital for all Australians to have regular skin checks. The Spot Detective campaign is encouraging Australians to visit a Spot Detective – their GP, dermatologist or skin health specialist – to have their spots assessed and to learn about the various treatments available for those diagnosed with non-melanoma skin cancer.

Skin cancer occurs when skin cells are damaged, often from overexposure to ultraviolet (UV) radiation from the sun. There are three main types of skin cancer: basal cell carcinoma (BCC); squamous cell carcinoma (SCC) and melanoma.2 Australia has one of the highest melanoma rates in the world1, with one Australian dying from melanoma every six hours.3 A skin check can save your life.

OncoBeta's Australian Medical Director, Dr Sam Vohra, says, "Thankfully most skin cancers are treatable and most of us will know someone who has had a skin cancer. Today, there are a range of treatments available to patients in addition to surgery, some of which are painless*, only needing a single session† and non-invasive."4-6

The Spot Detective campaign is asking Australians to take action: if they see a skin spot that is suspicious, new, oddly shaped or has changed in colour then it's time to get it checked. The campaign includes a series of LIVE reads across 2GB and WSFM in Sydney and 3AW and Gold 104.3 in Melbourne, as well as a social media and digital marketing campaign, and free skin check pop-ups at various locations.

More on ncarol.com
  • Larry R. Wasion Highlights Jump Gate I: Time Chair. The Opening Novel in His Expansive Science Fiction Series
  • K4Connect Launches Team Hub 5.0 — The Intelligent Execution Layer for Senior Living
  • New Book Reveals The Science Of Predictions
  • Compliance Alert: Maryland, Texas Regulate Use of Artificial Intelligence in Utilization Reviews
  • Colony Ridge Communities Celebrates Successful Soccer Season Kickoff with Families and Youth

"With one of the highest incidences of skin cancer in the world, Australians need to be vigilant with their skin. The Spot Detective campaign is a timely reminder to make sure you are protecting yourself from the sun, and if you notice any changes to your skin, check in with a skin health specialist," added Dr Vohra.

Another health initiative from OncoBeta, this public awareness campaign also encourages anyone diagnosed with non-melanoma skin cancer to be well informed about all treatments and discuss their most suitable options with a healthcare professional. OncoBeta's skin cancer therapy which utilises the rhenium-188 isotope is now available at private clinics at Melbourne and Sydney. Patients with difficult anatomic localisations of a tumour, such as the ear, nose or anywhere on the face, and those with larger lesions problematic for plastic surgery, may benefit from this non-invasive solution.

To find out more information on skin cancer, and to learn what treatments are available, visit: www.spotdetective.com.au

About OncoBeta® GmbH
OncoBeta® GmbH, with its headquarters located in Garching near Munich, Germany, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies. Since its foundation, OncoBeta has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting NMSCs. OncoBeta has perfected the customized application and device management system in conformity with all health, safety and environmental protection regulatory standards.

Find out more about the Rhenium-SCT® at www.oncobeta.com

Follow us on social media:

More on ncarol.com
  • NYC Composer/Educator Launches Debut Children's Book to Fantastic Reviews
  • EFA Announces 2026 Editorial Rate Chart
  • Red5 Taps PubNub to Power the Next Era of Real-Time Interactive Streaming
  • Yield Curve Shifts Drive Retail Traders to AI Trading for 126% Annualized Return Stability
  • Shoutout Joseph Neibich aka Nybyk

LinkedIn: https://www.linkedin.com/company/oncobeta-gmbh/
Facebook: https://www.facebook.com/oncobeta/
Instagram: https://www.instagram.com/oncobeta_gmbh/

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta's control, and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta's plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

*No reported pain.3
†
Complete tumour regression in 98.5% of lesions treated.

References:
1. Cancer Council. Understanding Skin Cancer. January 2020. https://www.cancercouncil.com.au/ (accessed October 2022).
2. Skin Cancer. Available at https://www.mayoclinic.org/diseases-conditions/skin-cancer/symptoms-causes/syc-20377605 [Accessed October 2022]
3. Melanoma Institute Australia. Melamoma Facts. https://melanoma.org.au/about-melanoma/melanoma-facts/ (accessed October 2022).
4. Castellucci P, et al. Eur J Nucl Med Mol Imaging. 2021; 48(5):1511–1521.
5. Cipriani C, et al. J Dermatol Treat. 2020; DOI: 10.1080/09546634.2020.1793890.
6. Cipriani C, et al. In Therapeutic Nuclear Medicine. 2014. RP Baum (Ed), New York: Springer.

Contact
Jane Morey
***@moreymedia.com.au


Source: OncoBeta GmbH

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • NEW MANAGEMENT BOOK: Creating a Joy-Centric Culture
  • Alternative Singer Songwriter Big Bus Dream, Proudly Releases, Passionate Decay March 25th
  • QuickTrack by Datalex Transforms Retail Promoter Management with Claude AI and Real-Time Insights
  • Kaltra Introduces Seasonal Discounts on Replacement Coils for Carrier, York, and Trane Chillers
  • Evolve Construction Mobilizes Commercial Storm Response Across Illinois With AI-Powered Damage Documentation and Public Adjusters Partnership
  • Kindred Management Group Announces Opening
  • The World's First Fully Regenerative Economy: Securing Energy, Food, and a Clean Planet
  • Cash Every Denomination Announces Hustlers Haven 2.0 (Legacy Edition) — Exclusively on Even April 24
  • The State of Law Firm Marketing: Top Companies, Awards, and Resources
  • USA Best Book Awards Finalist What Love Leaves Behind Releases March 24
  • Inkdnylon Custom Apparel Launches Cost-Saving System for Promotional Products and Custom Apparel in Chicago
  • ENTOUCH Named Finalist for 2026 North American Inspiring Workplaces Awards
  • Cleveland County Goat Farm NC Kikos Featured in "Feature Farmer Friday" Documentary
  • Tony Grundler Introduces Artificial Intelligence V.S. Avatar-Ian's
  • Hollywood's Elite Gather at the Annual WOW Creations Oscars Gifting Suite at the Universal Hilton
  • Where Were the Women? Reframing the Greek Revolution Through Contemporary Art
  • JGCMGS Details Architecture to Safeguard Assets From Unauthorized Phishing Scams
  • 21 Days: The Malta Deadline That Could Redraw the Finnish Online Casino Map
  • JEGS Launches Modern, Secure Payments Powered by PhaseZero.ai
  • U.S. Government Contracts in Excess of 38 Million Secured Through Partner, Establishing Multi-Year Defense Revenue Platform Through 2032: $BLIS
_catLbl0 _catLbl1

Popular on ncarol.com

  • Purple Heart Recipient Honored by Hall of Fame Son In Viral Tribute Sparking National Conversation on Service Fatherhood, Healing and Legacy - 105
  • National Expansion Ignited Across Amazon $AMZN, Chewy $CHWY & Walmart $WMT: NDT Pharmaceuticals, Inc. (Stock Symbol: NDTP) $NDTP
  • Lineus Medical's SafeBreak® Vascular Added to Alliant GPO Contract
  • Training Lofts Launches $1,099 Unlimited Training Membership Featuring Semi-Private Coaching, Nutrition Support, and Recovery Services
  • VENUS Goes Live on CATEX Exchange As UK Financial Ltd Activates The Premier Division Of The Maya Meme's League
  • Inkdnylon Custom Apparel Launches Cost-Saving System for Promotional Products and Custom Apparel in Chicago
  • 66% of US Bankruptcies Are Medical — So Americans Are Building Businesses That Cover Healthcare Emergencies
  • Amicly Launches as a Safety-First Social App Designed to Help People Build Real, Meaningful Friendships
  • Elder Abuse Case Against Healthy Traditions Owner Raises Questions As To The Dire Reality Of Abuse Against The Last Of The Baby Boomers
  • Pastor Saeed Abedini Releases THE TRUTH – Volume 1, A Deeply Personal Story of Faith, Struggle, and Redemption

Similar on ncarol.com

  • Newborn Care Network Introduces Clinical Standard to Bridge the Six-Week Postpartum Gap
  • Compliance Alert: Maryland, Texas Regulate Use of Artificial Intelligence in Utilization Reviews
  • A Cure In Sight Advances Ocular Melanoma Advocacy During Rare Disease Week 2026 in Washington, DC
  • Targeting the Billion-Dollar U.S. Countermeasure Market With AI-Driven Biodefense Platform: Lunai Bioworks (N A S D A Q: LNAI)
  • Forced Psychiatric Hospitalization Fails Vulnerable People: CCHR Urges Repeal Amid Rising U.S. Policies
  • Surging Into High-Performance AI With $AMD Partnership, Patent Expansion, and Strengthened Balance Sheet: Avalon GloboCare Corp. (N A S D A Q: ALBT)
  • Inkdnylon Custom Apparel Launches Cost-Saving System for Promotional Products and Custom Apparel in Chicago
  • Why Your Berberine Failed: RevGenetics Unveils the Absorption Gap Solution
  • Jet Set: The Ultimate Coachella Afterparty
  • CCHR Warns: Psychiatric Diagnoses Without Biological Proof Now Used to Justify Euthanasia
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute